Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A412WV | ISIN: US80880W2052 | Ticker-Symbol:
NASDAQ
25.06.25 | 20:36
5,425 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCILEX HOLDING COMPANY Chart 1 Jahr
5-Tage-Chart
SCILEX HOLDING COMPANY 5-Tage-Chart

Aktuelle News zur SCILEX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May ...5
SCILEX Aktie jetzt für 0€ handeln
MoScilex Holding Co - 8-K, Current Report2
05.06.Scilex announces dosing guide for gout medication GLOPERBA2
05.06.Scilex Holding Company Announces Publication on GLOPERBA Dosing Adjustments in Peer-Review Journal6
04.06.Scilex Holding Co - 8-K, Current Report4
16.05.Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional .21
14.05.Scilex Holding Co - 10-Q, Quarterly Report6
12.05.Scilex Holding Co - 8-K, Current Report2
01.05.Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of ...20
30.04.Scilex Holding Co - 8-K, Current Report7
30.04.Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule244PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
22.04.Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April ...13
21.04.Scilex Holding Co - 8-K, Current Report4
17.04.FDA Grants Scilex Holding Orphan Drug Status For Colchicine To Treat Pericarditis2
16.04.FDA erteilt Orphan-Status für Perikarditis-Medikament von Scilex10
16.04.FDA grants orphan status to Scilex's pericarditis drug1
16.04.Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis124Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Pericarditis is an inflammation of the pericardium...
► Artikel lesen
15.04.Kanada genehmigt Scilex' Migräne-Lösung ELYXYB11
15.04.Canada approves Scilex's migraine solution ELYXYB5
15.04.Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB's Acute Treatment of ...391ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1According to market data from 2018, it...
► Artikel lesen
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1